ArticlemAbs2016

Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.

Anette Karle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.